Viewing Study NCT05660993

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2026-01-27 @ 5:31 AM
Study NCT ID: NCT05660993
Status: UNKNOWN
Last Update Posted: 2022-12-21
First Post: 2022-12-13
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Sponsor: National Research Center for Hematology, Russia
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PET-adapted Treatment View
None Relapsed/Refractory Hodgkin Lymphoma View
None Nivolumab View
None BeGEV View